Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait
Radium-223 is the 1st nuclide medicine from the group of alpha emitters, its use is associated with an increase in overall survival, a delay to bone complications and a significant improvement the quality of life, proven placebo-controlled randomized studies in patients with castration-resistant pro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-01-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/908 |